Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an announcement.
Cinclus Pharma Holding AB has called its Annual General Meeting for 21 May 2026 in central Stockholm, offering shareholders the choice to attend in person or participate via postal voting. Shareholders must be registered in the Euroclear Sweden share register by 12 May 2026 and follow specific notice and documentation procedures, including proxy forms and voting right registrations for nominee-registered shares.
The meeting agenda covers standard annual items such as election of the chair, approval of the agenda, presentation of the CEO and auditors, and adoption of the income statement and balance sheet. The detailed instructions underscore the company’s adherence to Swedish corporate governance norms and aim to facilitate broad shareholder participation, reinforcing transparency and formal oversight of Cinclus Pharma’s financial reporting and executive remuneration practices.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a Stockholm-based pharmaceutical company focused on developing treatments for gastrointestinal diseases. The company operates in the life sciences sector and is listed in Sweden, with Euroclear Sweden AB maintaining its share register and a shareholder base that includes both directly registered and nominee-registered investors.
Average Trading Volume: 31,168
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK777.2M
For detailed information about CINPHA stock, go to TipRanks’ Stock Analysis page.